Psilocybin
Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer Patients
Reset Pharma is specifically honing in on the plight of cancer patients.
The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer…
Filament Health (OTCQB: FLHLF) has inked a licensing deal with biotech firm Reset Pharmaceuticals Inc. to test a psychedelic-based drug for treating a severe form of emotional distress.
Under the agreement, Filament will license its botanical psilocybin drug candidate, PEX010, to Reset Pharma for a phase 2 clinical trial.
“Clinical trial data indicates that psilocybin may be effective in treating demoralization syndrome,” said Jan-Anders Karlsson, co-founder and interim CEO of Reset Pharma.
While there’s growing interest in psychedelics as potential treatments for various mental health conditions, Reset Pharma is specifically honing in on the plight of cancer patients who grapple with intense feelings of demoralization, risking suicide, and currently lacking effective treatments.
“We believe that demoralization syndrome is a complex and under-examined area of study,” Filament CEO Benjamin Lightburn said in a statement. “We are thrilled to develop a partnership with Reset Pharma and look forward to the advancement of our drug candidate in this important field.”
Multiple other entities have already licensed Filament’s PEX010 for clinical trials, looking to address issues such as opioid addiction and alcohol-related disorders.
The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer Patients appeared first on Green Market Report.
psilocybin psychedelic psychedelics deal filament health filament-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance